The MET Pathway

Chapter 9

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss a newer potential target in RCC—MET.

Chapter 1

Targeted Therapy in Locally Advanced RCC

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss treatment options and ongoing research related to locally advanced renal cell carcinoma (RCC).

Chapter 2

The Role of Neoadjuvant Therapy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the role of neoadjuvant therapy in the treatment of patients with renal cell carcinoma (RCC).

Chapter 3

Surgical Options – Ablative Techniques

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the preferred surgical options for patients with kidney cancer.

Chapter 4

Surgical Options – Lymph Node

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the standards for decision making related to lymph node dissection in patients with renal cell carcinoma (RCC).

Chapter 5

Surgical Options – Cytoreductive Nephrectomy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the paradigm of cytoreductive nephrectomy and its role in the management of metastatic renal cell carcinoma (RCC).

Chapter 6

Tyrosine Kinase Inhibitors - First-Line Therapy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the use of tyrosine kinase inhibitors in patients with advanced renal cell carcinoma and how they differ from other targeted therapies.

Chapter 7

Tyrosine Kinanse Inhibitors – Second-Line Therapy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the use of tyrosine kinase inhibitors in the refractory renal cell carcinoma (RCC).

Chapter 8

Biomarkers in Renal Cell Carcinoma

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss biomarkers and how they relate to the treatment of advanced renal cell carcinoma (RCC).

Chapter 10

Checkpoint Inhibitors

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, review the role of checkpoint inhibitors in the treatment of patients with kidney cancer.

Speakers
Philip Kantoff, MD Brian I. Rini, MD, Professor of Medicine, Lerner College of Medicine and Leader of the GU Program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.
Andrew J. Armstrong, MD Steven Campbell, MD, PhD, Professor of Surgery, Residency Program Director, and a member of the Section of Urologic Oncology in the Glickman Urological and Kidney Institute at Cleveland Clinic in Cleveland, Ohio.
A. Oliver Sartor, MD David F. McDermott, MD, Director of the Biologic Therapy and Cutaneous Oncology Programs at Beth Israel Deaconess Medical Center; Leader of the Dana Farber/ Harvard Cancer Center Kidney Cancer Program and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
William K. Oh, MD Robert J. Motzer, MD, attending physician, genitourinary oncology service at Memorial Sloan-Kettering Cancer Center, and professor of medicine, Weill Medical College, Cornell University in New York, NY.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters